{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:16:26Z","timestamp":1790622986749,"version":"4.1.0"},"reference-count":30,"publisher":"BMJ","issue":"11","funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2017,10,15]]},"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate temporal trends in the use of non-vitamin K oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) in combination with aspirin and\/or clopidogrel in patients with atrial fibrillation (AF) following acute myocardial infarction (MI) and\/or percutaneous coronary intervention (PCI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using Danish nationwide registries, all patients with AF who survived 30 days after discharge from MI and\/or PCI between 22 August 2011 and 30 September 2016 were identified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 2946 patients were included in the study population, of whom 1967 (66.8%) patients were treated with VKA in combination with antiplatelet(s) (VKA+aspirin n=477, VKA+clopidogrel n=439, VKA+aspirin+clopidogrel n=1051) and 979 (33.2%) patients were treated with NOAC in combination with antiplatelet(s) (NOAC+aspirin n=252, NOAC+clopidogrel n=218, NOAC+aspirin+clopidogrel n=509). The overall study population had a median age of 76 years [IQR: 69\u201382] and consisted of 1995 (67.7%) men. Patients with MI as inclusion event accounted for 1613 patients (54.8%). Patients with high CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score(congestive heart failure, hypertension, age \u226575 years (2 points), diabetes mellitus, history of stroke\/transient ischemic attack\/systemic thromboembolism (2 points), vascular disease, age 65-75 years, and female sex) accounted for 132 2814 (95.5%) of patients, and patients with high HAS-BLED score (hypertension, abnormal renal\/liver function, history of stroke, history of bleeding, age &gt;65 years, non-steroidal anti-inflammatory drug usages, or alcohol abuse, leaving out labile international normalized ratio (not available), and use of antiplatelets (exposure variable)) accounted for 934 (31.7%) of patients. There was an increase from 10% in 2011 to 52% in 2016 in the use of NOACs in combination with antiplatelet(s).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>From 2011 to 2016, the use of NOAC in combination with antiplatelet(s) increased in patients with AF following MI\/PCI and exceeded the use of VKA in combination with antiplatelet(s) by 2016.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2017-311976","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T16:21:08Z","timestamp":1509553268000},"page":"912-920","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation"],"prefix":"10.1136","volume":"104","author":[{"given":"Caroline","family":"Sindet-Pedersen","sequence":"first","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"School of Medicine, New York University, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Staerk","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Lamberts","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Alexander","family":"Gerds","sequence":"additional","affiliation":[{"name":"Department of Research, Danish Heart Foundation, Copenhagen, Denmark"},{"name":"Department of Public Health, Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Berger","sequence":"additional","affiliation":[{"name":"School of Medicine, New York University, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Nissen Bonde","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannik","family":"Langtved Pallisgaard","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Lock","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark"},{"name":"Department of Health, Science and Technology, Department of Epidemiology\/Biostatistics and Cardiology, Aalborg University and Hospital, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar H","family":"Gislason","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Research, Danish Heart Foundation, Copenhagen, Denmark"},{"name":"National Institute of Public Health, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Bjerring Olesen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,11,1]]},"reference":[{"key":"2025092014350052000_104.11.912.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu298"},{"key":"2025092014350052000_104.11.912.2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH09-08-0580","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary intervention\/ stenting","volume":"103","author":"Lip","year":"2010","journal-title":"Thromb Haemost"},{"key":"2025092014350052000_104.11.912.3","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"2016","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2025092014350052000_104.11.912.4","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euu008"},{"key":"2025092014350052000_104.11.912.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.061"},{"key":"2025092014350052000_104.11.912.6","doi-asserted-by":"crossref","first-page":"ehw658","DOI":"10.1093\/eurheartj\/ehw658","article-title":"Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark","volume":"38","author":"Gadsb\u00f8ll","year":"2017","journal-title":"Eur Heart J"},{"key":"2025092014350052000_104.11.912.7","doi-asserted-by":"publisher","DOI":"10.1038\/srep31477"},{"key":"2025092014350052000_104.11.912.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.029"},{"key":"2025092014350052000_104.11.912.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.114967"},{"key":"2025092014350052000_104.11.912.10","doi-asserted-by":"publisher","DOI":"10.1177\/1403494810387965"},{"key":"2025092014350052000_104.11.912.11","doi-asserted-by":"publisher","DOI":"10.1177\/1403494810394717"},{"key":"2025092014350052000_104.11.912.12","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811401482"},{"key":"2025092014350052000_104.11.912.13","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811399956"},{"key":"2025092014350052000_104.11.912.14","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811399958"},{"key":"2025092014350052000_104.11.912.15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi705"},{"key":"2025092014350052000_104.11.912.16","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-015-6632-3"},{"key":"2025092014350052000_104.11.912.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"2025092014350052000_104.11.912.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"2025092014350052000_104.11.912.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"2025092014350052000_104.11.912.20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.832139"},{"key":"2025092014350052000_104.11.912.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105819"},{"key":"2025092014350052000_104.11.912.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112277"},{"key":"2025092014350052000_104.11.912.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60738-8"},{"key":"2025092014350052000_104.11.912.24","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"2025092014350052000_104.11.912.25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/clc.22572","article-title":"Design and rationale of the RE-DUAL PCI Trial: a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrilla","volume":"39","author":"Cannon","year":"2016","journal-title":"Clin Cardiol"},{"key":"2025092014350052000_104.11.912.26","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-013-9873-0"},{"key":"2025092014350052000_104.11.912.27","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish national patient registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"key":"2025092014350052000_104.11.912.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(02)00591-7"},{"key":"2025092014350052000_104.11.912.29","doi-asserted-by":"publisher","DOI":"10.1159\/000102143"},{"key":"2025092014350052000_104.11.912.30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/CLEP.S59156","article-title":"Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999-2012","volume":"6","author":"Schmidt","year":"2014","journal-title":"Clin Epidemiol"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2017-311976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:35:12Z","timestamp":1758404112000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2017-311976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,1]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,5,10]]},"published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1136\/heartjnl-2017-311976"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2017-311976","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,1]]}}}